Healthcare Industry News: rheumatoid arthritis
News Release - October 12, 2012
Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance OfficerTHOUSAND OAKS, Calif., Oct. 12, 2012 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced the appointment of Cynthia M. Patton to senior vice president and chief compliance officer, effective Oct. 22. In this role, Patton will report to Robert A. Bradway, president and chief executive officer, and will be responsible for Amgen's worldwide compliance and business ethics organization. She succeeds Anna Richo, who has resigned from the company effective Oct. 31 to join another global biopharmaceutical company as general counsel.
Patton joined Amgen in 2005, and was most recently a vice president in the Amgen law department with responsibility for commercial legal activities in the United States. Previously, she served as the lead commercial lawyer for both the oncology and inflammation business units.
"Cynthia has more than 20 years of healthcare legal experience and a deep understanding of our business operations," Bradway said. "Cynthia's addition to Amgen's leadership team will help us further our commitment to conduct business ethically and in compliance with the laws and regulations that govern our business and industry."
Before joining Amgen, Patton served for seven years as the general counsel of a California HMO. Patton received her J.D. from George Washington University and her bachelor's degree from Vassar College.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEuropean Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia